Fixed dose Ledipasvir/sofosbuvir in genotype 3 patients, genotype 1 patients with decompensated liver or prior treatment with sofosbuvir.
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 25 Jun 2014
Price : $35 *
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 25 Jun 2014 New trial record
- 13 Apr 2014 Results presented at the 49th Annual Meeting of the European Association for the Study of the Liver.